Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Rating Lowered by Zacks Research

Amneal Pharmaceuticals (NASDAQ:AMRX) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Monday, Zacks reports.

A number of other brokerages also recently issued reports on AMRX. Barclays upped their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. UBS Group raised their price target on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Weiss Ratings upgraded shares of Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 26th. JPMorgan Chase & Co. restated an “overweight” rating and issued a $22.00 target price on shares of Amneal Pharmaceuticals in a report on Wednesday, August 26th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $21.00 price target on shares of Amneal Pharmaceuticals in a research note on Friday, July 31st. Seven equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $19.00.

Amneal Pharmaceuticals Stock Down 2.2%

NASDAQ AMRX opened at $17.05 on Monday. The stock has a 50 day moving average price of $17.76 and a 200-day moving average price of $15.00. Amneal Pharmaceuticals has a one year low of $9.49 and a one year high of $19.26. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. The company has a market capitalization of $5.44 billion, a P/E ratio of 34.80 and a beta of 1.24.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.06. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. The company had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. As a group, equities analysts predict that Amneal Pharmaceuticals will post 0.94 EPS for the current fiscal year.

Insider Activity at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, EVP Jason B. Daly sold 210,000 shares of Amneal Pharmaceuticals stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the completion of the sale, the executive vice president directly owned 35,171 shares of the company’s stock, valued at $611,975.40. The trade was a 85.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Nikita Shah sold 146,403 shares of the company’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total value of $2,563,516.53. Following the completion of the sale, the executive vice president owned 253,390 shares of the company’s stock, valued at $4,436,858.90. This represents a 36.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 413,016 shares of company stock worth $7,216,567. Company insiders own 17.30% of the company’s stock.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several large investors have recently modified their holdings of AMRX. Public Employees Retirement System of Ohio bought a new position in shares of Amneal Pharmaceuticals during the second quarter valued at approximately $29,000. Kemnay Advisory Services Inc. bought a new stake in Amneal Pharmaceuticals during the 4th quarter valued at $26,000. Federated Hermes Inc. increased its holdings in shares of Amneal Pharmaceuticals by 1,680.6% in the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock valued at $29,000 after acquiring an additional 2,168 shares during the period. Transamerica Financial Advisors LLC raised its position in shares of Amneal Pharmaceuticals by 541.9% in the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock worth $37,000 after acquiring an additional 2,460 shares in the last quarter. Finally, Comerica Bank boosted its position in Amneal Pharmaceuticals by 186.7% during the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after purchasing an additional 1,957 shares in the last quarter. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.